The burgeoning popularity of semaglutide , initially for blood sugar control , is creating significant buzz within the UK , prompting a notable shift in hormone trends. Access these compounds remains a complex landscape, with public healthcare system coverage currently limited and specialist practices offering therapy at a premium . Worries are bei